Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Files Tekturna/Hydrochlorothiazide Combination For Blood Pressure

This article was originally published in The Pink Sheet Daily

Executive Summary

Company presents pivotal data on the diuretic/renin inhibitor combo at the American Society of Hypertension meeting.
Advertisement

Related Content

Novartis/Speedel’s Tekturna-Diuretic Combination Clears FDA
Novartis/Speedel’s Tekturna-Diuretic Combination Clears FDA
Phase III Tekturna Diabetes Data Could Further Differentiate Drug From Competing Hypertension Products
Phase III Tekturna Diabetes Data Could Further Differentiate Drug From Competing Hypertension Products
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension
Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension

Topics

Advertisement
UsernamePublicRestriction

Register

PS066067

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel